Strategic Collaboration Forms to Offer Companies Integrated Biopharmaceutical Solutions
A collaboration between Rentschler Biopharma and Coriolis Pharma has been formed that will draw upon complementary scientific and technical expertise to provide end-to-end solutions for the biopharmaceutical value chain.
Global CDMO, Rentschler Biopharma, and global contract research and development organization (CRDO), Coriolis Pharma, have formed a strategic collaboration to provide integrated biopharma solutions to meet the evolving needs of the biologics market. The integrated service offering will be available to the companies’ clients from December 2025.
Through the collaboration, the companies will combine their complementary expertise to offer their clients end-to-end solutions ranging from early formulation all the way through to commercial manufacturing. Benefits of the collaborative approach include a unified interface and aligned project teams, reduced tech transfer risks, and faster progression through the development lifecycle.
“This marks an important step for both our organizations and for our global clients, and their patients,” said Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma, in a company press release (1). “Coriolis Pharma shares our focus on technical excellence, reliability, as well as our client-centric approach. By bringing together our individual areas of excellence, bioprocess development and manufacturing on our side, and scientific and analytical expertise in formulation development at Coriolis, we look forward to addressing complex challenges across the biopharmaceutical value chain more efficiently and faster. This collaboration perfectly exemplifies our vision of advancing medicine to save lives. Together.”
“At Coriolis, we believe that scientific excellence, client-focused innovation, and strong partnerships are key to advancing complex biopharmaceutical programs efficiently and reliably. With Rentschler Biopharma, we have a trusted partner whose process development and manufacturing expertise ideally complements our deep understanding of formulation development and analytical services,” added Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis Pharma, in the press release (1). “This collaboration is a testament to our Coriolis partnering strategy, which fosters synergistic relationships across the biopharma ecosystem. Together, we can provide clients with connected, science-driven solutions that help them move their projects forward towards success. Our teams look forward to working closely with Rentschler Biopharma on this collaboration.”
The biologics market is experiencing growth as a result of the rising burden of chronic diseases, accelerated regulatory approvals and designations, expansion of biosimilar adoption, continued innovation in biologic modalities, increase in outsourced biologics manufacturing capacity, and higher healthcare expenditure in emerging markets. Analysts have predicted that the market will grow by a compound annual rate of 10.49% over the next five years, reaching a value of USD 679.56 billion in 2030 (2).
References
Rentschler Biopharma. Rentschler Biopharma and Coriolis Pharma Announce Strategic Collaboration for Integrated Biopharma Solutions. Press Release, Dec. 2, 2025.
Mordor Intelligence. Biologics Market Size and Share Analysis — Growth Trends and Forecast (2025–2030). Market Research Report, Nov. 24, 2025.